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Abstract
Background This study aimed to gain insight into the
optimal spacing in time for visual field tests for progression
detection in glaucoma.
Methods Three perimetric strategies for progression detec-
tion were compared by means of simulation experiments in
a theoretical cohort. In strategies 1 and 2, visual field
testing was performed with fixed-spaced inter-test intervals,
using intervals of 3 and 6 months respectively. In strategy
3, the inter-test interval was kept at 1 year as long as the
fields appeared unchanged. Then, as soon as progression
was suspected, confirmation or falsification were performed
promptly. Follow-up fields were compared against a
baseline assuming linear deterioration, using various pro-
gression criteria. Outcome measures were: (1) specificity,
(2) time delay until the diagnosis of definite progression,
and (3) number of required tests.
Results Strategies 2 and 3 had a higher specificity than
strategy 1. Strategies 1 and 3 detected progression earlier
than strategy 2. The number of required visual field tests
was lowest for strategy 3.
Conclusion Perimetry in glaucoma can be optimised by
postponing the next test under apparently stable field
conditions and bringing the next test forward once
progression is suspected.
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Introduction
Perimetry is currently the most widely used diagnostic
technique for the detection of progression in glaucoma.
Traditionally, perimetry is performed at fixed-spaced inter-
test intervals. Inter-test intervals of 3 months have been
shown to be optimal [1, 2], while intervals of 6 months are
considered an acceptable compromise between information
yield and costs [3].
The fixed-spaced nature of inter-test intervals is not
grounded in firm evidence. In fact, a recent study has
suggested that fixed-spaced inter-test intervals are not
optimal [4]. It was argued in that study that the next test
could be postponed in the case of an apparently stable field,
and should be brought forward once progression is
suspected. This so-called adaptive testing should allow for
earlier diagnosis and a lower overall perimetric frequency.
The superior performance of this adaptive approach arises
as a consequence of Bayes’ theorem - due to the low prior
probability of progression, apparent stability needs less
confirmation than suspected progression [5].
The above-mentioned study took the form of a thought
experiment assuming glaucomatous deterioration to be a
process occurring stepwise. Whether glaucomatous deteri-
oration is a stepwise or a continuous process has not yet
been settled. Stepwise progression has been reported, but
arguments in favour of continuous loss have also been
published [6–8].
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The aim of the present study is to investigate whether
adaptive testing is more efficient than fixed-spaced inter-
test interval testing for glaucomatous deterioration
occurring continuously. Three perimetric strategies were
compared for this purpose. In strategies 1 and 2, testing was
performed with fixed-spaced inter-test intervals using
intervals of 3 and 6 months respectively. In strategy 3, the
inter-test interval was kept at 1 year as long as the fields
appeared unchanged. Then, as soon as progression was
suspected, confirmation or falsification were performed
promptly. These three strategies were compared by means
of simulation experiments in a theoretical cohort assuming
linear deterioration, using two different progression criteria,
one based on nonparametric ranking [5], and the other on
the AGIS criterion [9]. Outcome measures were: (1)
specificity, (2) time delay until the diagnosis of definite
progression, and (3) number of required tests.
Materials and methods
A visual field test result was represented by a single real
number x. This number could, for instance, represent a
global index parameter such as mean deviation (MD) or the
AGIS score [9, 10]. Perimetric variability was modelled by
adding a normally distributed random number e with mean
0 and standard deviation SD to x. In this study, 4,000
independent series of normally distributed random numbers
were generated using ASYST 3.10 (Asyst Software
Technologies, Rochester, NY, USA) to construct 4,000
series of visual field test results. This large number was
chosen in order to minimize the influence of chance on the
final results. Deterioration was modelled as a linear decay
at rate r. Hence:
x tð Þ ¼ x 0ð Þ  rt þ e ð1Þ
where t is the time since the start of the follow-up.
Calculations were performed in stable series—i.e., with
r=0—to assess specificity, and with three different rates of
glaucomatous deterioration: r=0.5, 1.0, and 2.0 SD/yr.
These values roughly correspond to 1, 2 and 4 dB/yr loss of
MD [8]—i.e., an SD corresponds to 2 dB. Rates of 1–2 dB/
yr are typical of glaucoma patients with progression [8];
4 dB/yr was added in order to study the performance of the
various strategies in patients with a higher than average rate
of progression.
A test result worse than a predefined baseline was
denoted as suspected progression. For the diagnosis of
definite progression, two confirmations of this suspected
progression were required—i.e., three consecutive follow-
up fields had to have scores worse than the predefined
baseline. In criterion I, the predefined baseline was defined
as the worse score of two baseline fields [5]. In criterion II,
the predefined baseline was defined using an offset D from
a reference baseline field [9]. For AGIS, D=1.6 SD (see
Discussion) [9].
Calculations were performed for three different strategies
for visual field test spacing. In strategies 1 and 2, testing
was performed with fixed-spaced inter-test intervals using
intervals of 3 and 6 months respectively. In strategy 3, the
inter-test interval was kept at one year (see Discussion) as
long as the fields appeared unchanged. Then, as soon as
progression was suspected, confirmation or falsification
were performed promptly.
Results
Figure 1 shows the proportion of the cohort with definite
progression as a function of follow-up time for strategies 1–
3 for stable series (a; r=0) and for three different rates of
progression (b; r=0.5, 1.0 and 2.0 SD/yr), using criterion I.
Specificity was lowest for strategy 1—i.e., strategy 1 had
the highest incidence rate of definite progression for stable
fields (Fig. 1a). Strategy 2 yielded a delayed diagnosis of
definite progression when compared with strategies 1 and 3
(Fig. 1b). Figure 2 presents the corresponding results using
criterion II with offset D=1.6 SD. Again, specificity was
lowest for strategy 1 (Fig. 2a) and strategy 2 showed a
delayed diagnosis of definite progression (Fig. 2b).
Table 1 shows the average number of tests performed up
to the diagnosis of definite progression for all three
strategies for both stable series (r=0) and three different
rates of progression (r=0.5, 1.0 and 2.0 SD/yr), using
criterion I. Where a series did not reach definite progression
within the 4-year follow-up, the number of tests performed
during the entire follow-up period was counted. Table 2
presents the corresponding results using criterion II with
offset D=1.6 SD. In all situations, the lowest number of
tests was required when using strategy 3.
Discussion
In this study, three perimetric strategies for progression
detection in glaucoma were compared; one with a fixed-
spaced inter-test interval of 3 months (1), one with a fixed-
spaced inter-test interval of 6 months (2) and one with
adaptive inter-test intervals (3). Strategy 1 had the lowest
specificity. Strategy 2 detected progression later than
strategies 1 and 3. The lowest number of tests was required
for strategy 3.
The differences in the numbers of required visual field
tests in the 4-year period for the three different strategies
were most apparent for r=0, i.e., for patients without
deterioration (Tables 1 and 2). Since in reality only a
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minority of glaucoma patients displays progression [13],
the overall perimetric frequency will mainly be determined
by the stable patients. Hence, strategy 3 does in fact have
the lowest overall perimetric frequency.
The offset D=1.6 SD as used in the current study was
based on AGIS [9]. A comparison between Figs. 1 and 2
clearly reveals a higher specificity and a lower sensitivity
for criterion II when compared to criterion I. This finding in
simulation experiments is in agreement with analyses of
measured patient data using various criteria for progression,
demonstrating a high specificity and a low progression rate
for the AGIS criterion [11, 12].
The original AGIS threshold was 4 AGIS units and the





































Fig. 1 Proportion of the cohort with diagnosed definite progression as a
function of the follow-up period for stable series of fields (a) and for series
with three different rates of glaucomatous deterioration: 0.5, 1.0 and
2.0 SD/yr (b), for strategies 1 , 2 and 3 , using





































Fig. 2 Proportion of the cohort with diagnosed definite progression as a
function of the follow-up period for stable series of fields (a) and for series
with three different rates of glaucomatous deterioration: 0.5, 1.0 and
2.0 SD/yr (b), for strategies 1 , 2 and 3 , using
criterion II (AGIS criterion)
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population was 2.5 units [9], together resulting in the
1.6 SD threshold as used in this study. In reality, some
patients display above average variability whereas others
display below average. For that reason, situations with
above and below average perimetric variabilities were also
explored. Within a realistic range of perimetric variabilities,
strategy 3—i.e., the strategy with adaptive inter-test
intervals, remained the most efficient (data not shown).
An implicit assumption in this study was that each visual
field test performed could be scored—i.e., each test was
assumed to be reliable. Obviously, this is not the case in
clinical reality, and unreliable tests have to be repeated.
Hence, more tests may be needed in reality as compared to
theory. It is reasonable to assume, however, that the
proportion of unreliable tests does not depend on the
strategy applied. Thus, also in the presence of unreliable
tests, strategy 3 will remain the most efficient approach.
The interval of one year used here in the adaptive
approach was based on two facts: (1) that it takes on
average 1 year to build up a prior probability of progression
of 10%, and (2) that it is virtually impossible to detect
progression with a prior probability of less than 10% in
clinical practice [5, 13]. In poorly regulated patients, the
10% prior probability of progression will be reached within
a year; therefore, a shorter inter-test interval should be used.
Conversely, some other patients may be sent home safely
for longer than a year. Generally, known risk factors for
progression may be incorporated into the model by adjust-
ing the inter-test interval of the adaptive approach. Disease
stage (MD, AGIS score) could be such a risk factor [14].
As mentioned in the Introduction, it is largely unknown
whether glaucomatous deterioration is a continuous or a
stepwise process. This question cannot easily be solved,
because the phenotype of continuous loss may resemble
that of stepwise progression, and vice versa, due to
perimetric variability and discrete sampling. Both types of
progression have been reported [6, 7]. The current study
showed adaptive testing to be the preferred approach for
continuous loss; an earlier study yielded the same conclu-
sion for stepwise progression [4]. Therefore, it seems
reasonable to conclude that adaptive testing is the most
efficient approach irrespective of what the exact underlying
nature of glaucomatous deterioration is.
In some cases, especially in elderly patients with early
glaucoma, it may be of more importance to monitor the rate
of progression than the occurrence of any progression. This
can also be achieved using adaptive testing - small changes
may be accepted without a prompt confirmation. Where a
change occurs that could exceed the acceptable rate of
progression, however, the next test should be brought
forward. After all, fixed-spaced inter-test intervals are not a
prerequisite for slope determination (linear regression can
be applied to any set of datapoints without the need to
assume that the points are equally spaced along the x-axis).
In the case of new patients, it cannot be known in
advance whether they represent stable or deteriorating
cases. As a consequence, adaptive testing cannot be applied
from the outset. Perimetry in a new patient has to start at a
relatively high perimetric frequency, such as one visual
field test every 3 months. As soon as stability has been
shown, a switch can be made to adaptive testing.
Finally, it should be emphasized that the findings as
presented here are by no means specific to perimetry. As a
consequence, these findings can be applied to the monitor-
ing of any variable that has normal variability, both within
and outside the field of glaucoma. The only prerequisite is
that the prior probability of change is small.
In conclusion, perimetry in glaucoma can be made more
efficient by postponing the next test under apparently stable
field conditions (typically 1 year) and bringing the next test
forward once progression is suspected.
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